No title
Background: The utility of whole-genome sequencing (WGS) in diagnosing cardiomyopathies (CM) and heritable connective tissue disorders (HCTD) is limited by high costs and ambiguous results. Letting the referring physician decide whom to refer for WGS increases the absolute number of positive patients identified but lowers clinical yield (proportion of patients identified with a pathogenic gene var
